The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi.
In the transaction, Blueprint insiders received substantial benefits as part of change of control arrangements and certain insiders may have had conflicts of interests.
We are investigating whether the transaction offering documents may have contained materially misleading information and/or omissions.
Join this Action